Brief: Milestone Pharmaceuticals Posts Q4 Loss Per Share $0.31
29/03/2023 16:10
March 29 (Reuters) - Milestone Pharmaceuticals Inc
MIST.O :
* MILESTONE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL
YEAR
2022 FINANCIAL RESULTS AND PROVIDES CLINICAL AND CORPORATE
UPDATE
* NDA SUBMISSION FOR ETRIPAMIL IN PATIENTS WITH PSVT
EXPECTED FOR
3Q23
* QTRLY LOSS PER SHARE $0.31
* YEAR-END CASH RESOURCES EXPECTED TO FUND OPERATIONS INTO
MID-2025
* Q4 EARNINGS PER SHARE VIEW $-0.34 -- REFINITIV IBES DATA
Source text for Eikon: ID:nCNWKL3Ppa
Further company coverage: MIST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview